Introduction
Airway remodeling is progressive airway damage and structural changes can be caused by long-term recurrent asthma. Airway remodeling can occur at the early stage of the disease and cause an irreversible persistent airflow obstruction and a gradual decline in lung function in asthma patients [1] . It is critical to further understand the mechanism of airway remodeling and search for the prevention and treatment of remodeling in patients with asthma.
Although inhalation of corticosteroids supplemented [2] by sputum induction is an effective thera py for the control of airway inflammation and asthma symptoms, airway remodeling is actually not restrai ned during the development of asthma [3] . In addition, there are many side effects that may lead to patients discontinuing the therapy [4] . As one of the most effective therapies, DNA vaccine has tur ned out to be a promising novel type of immuno therapy against allergy [5] . In previous studies, HSP70/CD80 DNA vaccine showed strong inhibition of airway hyperresponsiveness and airway inflammation in an asthmatic mouse model. The related mechanism may be attributed to the increase of interferon-γ (IFN-γ), strength of Th1-type response and changes of the immune balance [6] .
The aim of the present study was to demonstrate whether HSP70/CD80 DNA vaccine could inhibit airway remodeling in chronic asthmatic mouse and reveal the potential mechanisms.
Material and methods

P Pr re ep pa ar ra at ti io on n o of f H HS SP P7 70 0/ /C CD D8 80 0 D DN NA A v va ac cc ci in ne e
The HSP70 gene of mycobacterium tuberculosis and human CD80 were linked together and then cloned into the pcDNA3.1 eukaryotic expression vector. Details of the construction and identification were described in our previous studies [7] . In the present study, large scale preparation of the plasmid HSP70/CD80 was conducted with EndoFree Plasmid Giga Kit (QIAGEN GmbH, Germany) according to the manufacturer's instructions. Plasmids were dissolved in normal saline and adjusted to 1 mg/ml and stored at -20°C.
A An ni im ma al ls s a an nd d a an nt ti ig ge en n c ch ha al ll le en ng ge ed d a ai ir rw wa ay y r re em mo od de el li in ng g
Female BALB/C mice, 6-8 weeks old, were purchased from the Third Military Medical University and housed in a specific pathogen-free facility. The present study was approved by the Institutional Animal Care and Use Committee and adhered to the principles outlined by the Declaration of Helsinki.
Forty BALB/c mice were divided randomly into a con trol group, chronic asthma group, pcDNA3.1 group and DNA vaccine group. On days -42, -28 and -14, the pcDNA3.1 group was immunized with pcDNA3.1 plasmid (100 µg + 25 µg bupiva caine/ mouse) by intramuscular injection, the DNA vaccine group was treated with HSP70/CD80 (100 µg + 25 µg bupivacaine/mouse) by intramuscular injection, and the control group and asthmatic group were treated with phosphate-buffered saline (PBS + 25 µg bupivacaine/mouse). Bupivacaine (Jiangsu Hengrui Medicine, Jiangsu, China) is a new class of DNA delivery complexes [8] . Mice were intraperitoneally sensitized using OVA (Sigma-Aldrich, St. Louis, USA) at a concentration of 0.01 mg/mouse in 0.2 ml of alum on days 0 and 14. Mice were challenged with 1% OVA (aerosolized for 30 min) via the airways between days 21 and 26. Prolonged challenge was induced by subsequent exposure to aerosolized OVA (1%) three times a week for 30 min from day 28 to day 70 ( Figure 1 ) in a modified version of McMillan et al.' methods [9] . Control mice were injected and challenged with saline. Mice were then sacrificed by cervical dislocation after anesthesia on day 70. M Me ea as su ur re em me en nt t o of f a ai ir rw wa ay y r re es sp po on ns si iv ve en ne es ss s
Twenty-four h after the final challenge, wholebody ple thys mo graphy (WBP system, BUXCO, Wilmington, North Carolina USA) was used to measure airway responsiveness. Increasing doses of methacholine (MCh, Wako, Osaka, Japan) (1.5, 3, 6, 24, and 48 mg/ml) were inhaled at approximately 3-min intervals, and enhanced pause (Penh) results were recorded. This protocol is a modification of the method of Kearley et al. [10] . B Br ro on nc ch ho oa al lv ve eo ol la ar r l la av va ag ge e c co ol ll le ec ct ti io on n a an nd d m me ea as su ur re em me en nt t o of f c cy yt to ok ki in ne es s
Before sacrifice, the mice were anesthetized by 2% pentobarbital sodium (Sigma-Aldrich, St. Louis, USA) with intraperitoneal injections. After tracheal Q Qu ua an nt ti if fi ic ca at ti io on n o of f g ge en ne er ra al l m mo or rp ph ho ol lo og gy y
Image analysis was performed on HE-stained lung sections using ImagePro Plus 6.0 (Media Cybernetics, USA). Digital photographs of four bronchioles at the same level from each group of mice were taken at 40× magnification and the outer perimeter (Po), internal perimeter (Pi), airway wall area (Awa), airway wall thickness (Awt) and airway basement membrane perimeter (Pbm) were measured. We used Po/Pi, Awa/Pb and Awt/Pbm to evaluate quantification of airway remodeling.
A As ss se es ss sm me en nt t o of f a ai ir rw wa ay y m mu uc cu us s p pr ro od du uc ct ti io on n Mucus-producing goblet cells were counted using PAS staining. Goblet cells of 5 to 10 consecu tive bronchioles from each group of mice were cate gorized according to a scoring method as follows [11] : less than 5% goblet cells are 0 points; 5-25% goblet cells are 1 point; 25-50% goblet cells are 2 points; 50-75% goblet cells are 3 points; more than 75% goblet cells are 4 points. The mean of each group was expressed as the histological goblet cell score.
A An na al ly ys si is s o of f e ex xt tr ra ac ce el ll lu ul la ar r m ma at tr ri ix x d de ep po os si it ti io on n
The tissues were observed for extracellular matrix deposition using Masson Trichrome stain. Four bronchioles at the same level from each group of mice were selected randomly, then digital photo graphs were taken at 40× magnification and conver ted into monochrome. Ten measurements of 20-µm lines perpendicular to the basement membrane were drawn from the four bronchioles of each mouse. The mean density of Masson Trichrome staining intensity was measured and expressed as pixels/µm 2 , by the method of Flood-Page [12] .
A As ss se es ss sm me en nt t o of f A AS SM M c ce el ll ls s
Proliferating cell nuclear antigen (PCNA) was identified as an antigen that is expressed in proliferating cells during S phase of the cell cycle. The sections of each group were also stained immunohistochemically using anti-PCNA antibody. ASM cells in bronchiolar regions were counted at 40× magnification. Positive cells for PCNA stained with the nuclei dark brown. Total ASM cells and ASM cells positive for PCNA were counted and averaged using a modified method [9] . Spleens were stored at -80°C until use. Total RNA was isolated from murine spleen tissue using RNAsimple Total RNA kit (TINGEN, Beijing, China) and thereafter reverse transcribed into cDNA using RNA PCR Kit (AMV) Ver. 3.0 (TaKaRa, Dalian, China). Primers of IFN-γ, IL-4, T-bet, GATA-3 and β-action were designed by Sangon Biotech (Shanghai, China). The sequence of primers was as follows (Table I) . Quan titative real-time PCR was performed on an iCycler iQ™ Real-Time PCR Detection System (BioRad, Hercules, CA, USA) according to the manufacturer's instructions for relative quantification. Rela tive expression of target genes was determined with the Pfaffl method according to the Bio-Rad iQ5 software system. S St ta at ti is st ti ic ca al l a an na al ly ys si is s 
Results
A
Ai ir rw wa ay y r re es sp po on ns si iv ve en ne es ss s
As seen in Figure 2 , airway responsiveness in sensitization of mice with allergen (chronic asthma group) was significantly increased at 6, 12, 24 and 48 mg/ml MCh-inhaled doses compared with control (p < 0.05). Mice treated with HSP70/CD80 DNA vaccine had an inhibition effect of airway responsiveness compared with chronic asthmatic mice (p < 0.05, more than 6 mg/ml MCh-inhaled doses). Treatment with pcDNA3.1 plasmid had little effect on airway responsiveness (Table II) .
I
In nh hi ib bi it ti io on n o of f a ai ir rw wa ay y w wa al ll l t th hi ic ck kn ne es ss s b by y D DN NA A v va ac cc ci in ne e
The effect of HSP70/CD80 DNA vaccine on airway remodeling in lung tissue histology was determined by staining lung tissue with HE (p < 0.05, Figure 3 ). Prolonged OVA challenge of chronic asthmatic mice results in increased airway wall thickness in comparison to control mice (p < 0.05, Figure 4 ). In contrast, airway wall thickness was reduced in lungs from mice treated with HSP70/CD80 DNA vaccine in comparison to chronic asthmatic mice (p < 0.05, Figure  4) . Treatment with pcDNA3.1 plasmid had little effect on airway wall thickness. There was no significant difference during infiltration of inflammatory cells in bronchioles of mice in each group (Table III) . R Re ed du uc ct ti io on n o of f m mu uc cu us s p pr ro od du uc ct ti io on n b by y D DN NA A v va ac cc ci in ne e As shown in Figure 5 , mucus-producing goblet cells were increased in the chronic asthmatic mice model in comparison to control mice (p < 0.05). HSP70/CD80 DNA vaccine treatment reduced the number of PAS-positive goblet cells in comparison to chronic asthmatic mice (p < 0.05, Figure 6 ). There was no significant difference between pcDNA3.1 plasmid and chronic asthmatic mice.
I In nh hi ib bi it ti io on n o of f e ex xt tr ra ac ce el ll lu ul la ar r m ma at tr ri ix x d de ep po os si it ti io on n b by y D DN NA A v va ac cc ci in ne e Subepithelial extracellular matrix deposition of chronic asthmatic mice was increased in comparison to control mice. Figure 7 and Table IV show that treatment with HSP70/CD80 DNA vaccine reduced peribronchiolar matrix deposition in comparison to chronic asthmatic mice. Treatment with pcDNA3.1 plasmid showed little effect on extracellular matrix deposition.
In nh hi ib bi it ti io on n o of f A AS SM M c ce el ll l p pr ro ol li if fe er ra at ti io on n b by y D DN NA A v va ac cc ci in ne e
Positive PCNA staining ASM cells showed as cells with dark brown elongated or round nuclei. Figure 8 shows that the chronic asthmatic mice model had an increase in the number of total and PCNA-positive ASM cells in the smooth muscle mass in comparison to control mice (p < 0.05). Treatment with HSP70/CD80 DNA vaccine significantly reduced the number of total and PCNA-positive ASM cells (p < 0.05, Figure 9 ) in comparison to chronic asthmatic mice. Treatment with pcDNA3.1 plasmid had little effect on the increase in ASM cell numbers (Table V) . E Ef ff fe ec ct t o of f D DN NA A v va ac cc ci in ne e o on n c cy yt to ok ki in ne e p pr ro od du uc ct ti io on n
The BAL fluid from all four groups of mice was recovered and analyzed for the presence of the Th1 Table II , the level of IFN-γ and ratio of IFN-γ/IL-4 in the BAL fluid of chronic asthmatic mice were lower than controls (p < 0.05). There was a striking increase in the amount of IFN-γ and ratio of IFN-γ/ IL-4 in BAL fluid from HSP70/CD80 DNA vaccinetreated mice in comparison to chronic asthmatic mice (p < 0.05). There was no significant difference in IL-4 BAL fluid of mice in each group (Table VI) . in n s sp pl le ee en n t ti is ss su ue e
Th1-type transcription factor T-bet and Th2-type transcription factor GATA-3 play the key role in diffe rentiation toward Th1 and Th2 cells. As shown in Table VII , expression of IFN-γ was increased in mice treated with HSP70/CD80 DNA vaccine, while expression of IL-4 was decreased in compari son to chronic asthmatic mice. Expression of GATA-3 in the chronic asthmatic mice was significantly higher than in control mice. Mice with HSP70/CD80DNA vac cine showed reduced expression of GATA-3. As shown in Table VII , the ratio of T-bet/GATA-3 mRNA in HSP70/CD80 DNA vaccine-treated mice was significantly higher than in asthmatic mice (p < 0.05).
Discussion
Heat shock protein (HSP)-derived peptides have been shown to promote the production of antiinflammatory cytokines in patients with chronic inflammatory disease, indicating that HSPs have immunoregulatory potential [13] . Heat-shock protein 70 (HSP70) can induce a Th1-type immune response and inhibits or arrests inflammatory damage [14] . Hsp70 was demonstrated to have anti-inflammatory responses in experimental models of au to - immunity [15] . One study revealed that HSP 70 can protect cells under stress and may become a thera peutic target in DM cause's aortic stiffness [16] . Complete T-cell activation requires two distinct signals, one delivered via the T-cell receptor, and the second a "co-stimulatory" signal through B7/CD28 ligation. Some seminal reports suggested that liga tion of CD28 to B7-1 (CD80) had effects on the promotion of a Th1 phenotype [17] . We postulated that inoculation of HSP70 and CD80 might affect the development of airway remodeling because expression of HSP70 and CD80 is regulated in the immune imbalance following allergen challenge. In the present study, administration of HSP70/CD80 DNA vaccine before being sensitized and challenged by OVA during prolonged allergen challenge reduced airway remodeling by decreases in airway responsiveness, airway wall thickness, mucus-producing goblet cells, subepithelial extracellular matrix deposition and ASM cells. We observed very little antiremodeling effect in pcDNA3.1 plasmid-treated mice as compared with control mice. This is presumably because CpG dinucleotide contained by pcDNA3.1 is an immu nostimulatory agent [18] . Studies have shown that CpG oligodeoxynucleotide treatment inhibits airway inflammatory cell infiltration in an asthmatic mouse model [19, 20] . We have also shown that CpG dinucleotide in pcDNA3.1 has an effect on immune adjuvants and therapeutic administration of HSP70/CD80 DNA vaccine reduces the development of airway remodeling.
Human asthma is heterogeneous in terms of genetics, severity and in all likelihood pathophysiology. The differences between human allergic asthma and mouse models included the disease process, techniques for pulmonary function measurement, and species differences in expression of or respon ses to key cytokines [21] . No animal model completely recapitulates all features of the human disease. Modeling chronic asthma is controversial, because longterm antigenic challenge often leads to eventual downregulation of airway hyperreactivity or triggers extensive pulmonary inflammation [22, 23] . Our protocol in models of experimentally induced chronic asthma included an important modification of the protocol described by McMillan originally. BALB/c mice sensitized to OVA in the study were challenged for aerosolized OVA (1%) three times a week for 30 min over a period of up to 8 week in a whole-body inhalation exposure system. The mice maximized the exhibition of airway wall remode ling changes as seen in human asthma [24] . However, no animal model completely recapitulates all features of the human di sease. We recognize the limitations of murine models for the study of chro nic asthma which entail that results cannot be direc tly translated into clinical practice, but we hope the results will offer opportunities for investigation of pathogenetic mechanisms and novel thera peutic agents.
It is now widely accepted that T cells play a criti cal role in the pathogenesis of asthma which is based on a relative increase in Th2 responses in combination with a decrease in Th1 responses [25] . The mechanisms of Th1/Th2 differentiation induced by T-bet/GATA-3 at the molecular level have been identified. T-box transcription factor T-bet regulates differentiation to the Th1 lineage by inducing lineagerestricted target genes, such as IFN-γ and IL-12 genes [26] , and GATA-3 regulates differentiation to Th2 by inducing genes for IL-4, IL-5 and IL-13 [27, 28] .
T-bet expression is strongly correlated with IFN-γ expression and is specifically up-regulated in primary Th cells that differentiate along the Th1 pathway [29] . GATA-3 has been reported to induce chromatin structure changes of the IL-4 locus and in crease the production of Th2-type cytokines by regulating STAT6 [30] . Other research suggests that SAP induces NKT cell development and cytokine IL-4 and IFN-γ produc tion by promoting expression of GATA-3 and T-bet [31] . In this respect, our data demonstrated that expression of T-bet/GATA-3 is significantly increased after administration of HSP70/CD80 DNA vaccine. The expression occurred concomitantly with in creased IFN-γ, decreased mucus production, extracellular matrix deposition and ASM cell proliferation. In contrast, we found no change in levels of Th2 cytokine IL-4 and the expression of IFN-γ/IL-4 in spleen. It has also been reported that IFN-γ inhibits airway remode ling induced by Th2 and non-Th2 responses [32] . Consistent with this, our present study showed unchanged levels of IL-4 and a marked increase in the IFN-γ level in BALF. Alternatively, it is possible that the results reflect the small number of mice studied or HSP70/CD80 DNA vaccine has a weak effect in regulation of Th2 responses in the research.
In conclusion, we have shown that HSP70/CD80 DNA vaccine can reduce airway remodeling by regu lating the transcription factors T-bet and GATA-3 and influencing the immunologic response toward a Th1-type pattern. We believe that the results in this study may provide the basis for developing a more effective therapeutic DNA va ccine to prevent and treat airway remodeling in asthma.
